Expression of Toll-like receptors in the kidney: their potential role beyond infection  by Schroppel, B. & He, J.C.
Kidney International (2006) 69       785
commentar y
present the cold preservation market is 
notably short of competitors.
There is now a resurgence of inter-
est in machine perfusion of kidneys 
— continuous pumping of cold solution 
through the kidney. Once a minority 
interest, this technique is now gaining 
acceptance because of an increasingly 
held view that it results in a much lower 
rate of delayed graft  function.10 Clearly 
it will be important to compare PBS140 
with UW solution in conventional kid-
ney transplantation, but it may become 
equally relevant to test it against machine 
perfusion.
The real challenge now lies in the 
preservation of kidneys from marginal 
donors. As the demand for transplanta-
tion increases and the supply of ‘ideal’ 
organs (typically from young, heart-
beating donors) decreases, organs are 
now routinely transplanted from donors 
that would have been rejected in the past. 
Th ese include older donors, those with 
cardiovascular disease, those on large 
doses of inotropic support, and, par-
ticularly, non-heart-beating donors. It is 
this last group that is increasing rapidly, 
partly as a result of changing neurosur-
gical practice. Organs from non-heart-
beating donors experience a period of 
warm ischemia before cold preservation. 
Th is combination of injuries is associated 
with a much higher rate of acute tubular 
necrosis and delayed graft  function. Th e 
results reported by Ahmad et al. in this 
issue are important not just because these 
demonstrate the potential of another 
cold preservation solution, but because 
the experiments were carried out specifi -
cally to investigate preservation during 
warm ischemia — as seen in the situa-
tion of the non-heart-beating donor. It 
is possible that non-heart-beating donor 
renal transplantation will prove to be the 
niche that enables PBS140 to break into 
the preservation market.
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Expression of Toll-like receptors 
in the kidney: their potential role 
beyond infection
B Schröppel1 and JC He1
Toll-like receptors (TLRs) recognize both exogenous microbial 
components and endogenous molecules to promote immune 
activation. Both immune and nonimmune renal cells express TLRs, 
which are involved in the pathogenesis of a number of kidney diseases, 
including pyelonephritis, Leptospira nephritis, immune-complex 
glomerulonephritis, ischemic/reperfusion injury, and rejection of 
kidney transplant.
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Th e immune system in mammals consists 
of innate and adaptive immunity. The 
adaptive immune system is a sophisticated 
system mediated by antigen-specifi c T cells 
and B cells. Th e innate immune system is 
phylogenetically conserved and is the fi rst 
line of host defense against pathogenic 
microorganisms. Recently, great interest 
in innate immunity has emerged with the 
discovery of special germ line-encoded 
pathogen-pattern recognition recep-
tors called Toll-like receptors (TLRs). It 
appears that TLRs control activation of 
adaptive immune responses.1 To date, 11 
human and 9 murine proteins related to 
the Drosophila Toll gene have been char-
acterized.1–3 Th ese receptors specifi cally 
recognize pathogen-associated molecular 
patterns that are expressed on or in infec-
tious agents, including lipopolysaccharide, 
lipoprotein, peptidoglycan, bacterial DNA, 
and viral double-stranded RNA.1–3 Upon 
ligand binding, TLR-mediated signaling 
activates signal transduction pathways 
(such as nuclear factor-κB, c-Jun NH2-
terminal kinase/p38, nuclear factor/inter-
leukin-6, and interferon regulatory factor) 
that induce cytokines, chemokines, and 
increased expression of cellular mem-
brane proteins related to infl ammatory 
responses.1–3 Identifying endogenous 
ligands has generated evidence that TLR 
signaling contributes to infl ammation in 
the absence of microbes. Th ese ligands 
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include heparan sulfate, heat-shock pro-
teins, oligomers of hyaluronan, fi brinogen, 
and necrotic cells.1,2
Infection with Leptospira can induce 
acute tubulointerstitial nephritis and acute 
renal failure, probably caused by direct 
invasion of the organism into the kidney. 
Pathogenic Leptospira outer membrane 
contains lipopolysaccharide, glycolipid, 
and lipoproteins that determine virulence 
and are the main targets of immunity. 
Yang et al. have previously shown that 
Leptospira outer membrane proteins can 
activate nuclear factor-κB in medullary 
thick ascending limb cells4. Infl ammation 
and macrophage recruitment play a rele-
vant role in the detrimental early events of 
disease that occurs aft er human Leptospira 
infection. In their paper published in this 
issue, Yang et al.4 show that TLRs, more 
specifi cally TLR2, are expressed in tubu-
lar epithelial cells (TECs) and that outer 
membrane proteins from the pathogenic 
Leptospira activate TLR2. The inflam-
matory responses mediated through the 
innate immune system may then alter 
the activity of the adaptive immune sys-
tem, thereby infl uencing disease outcome. 
Th is fi eld is in its early stages, and we do 
not know whether the targeting of TLRs 
in microorganism-induced interstitial 
nephritis has a benefi cial impact on the 
disease outcome.
Both immune and nonimmune cells 
express inflammatory cytokines and 
chemokines upon stimulation of the TLR 
with their specifi c ligands, leading to tis-
sue damage, as this occurs in kidney (Fig-
ure 1). Although it is likely that TLRs are 
involved in the pathogenesis of a number 
of renal diseases, a paucity of data exists 
on their expression in the kidney and their 
role in renal disease. Th is was reviewed 
thoroughly by Anders et al.3 In addition 
to TECs, the nephron contains glomerular 
cells (endothelial cells, podocytes, mesang-
ial cells) and resident dendritic cells. Th e 
expression of TLRs in these cells and their 
role in innate immune response remain to 
be determined.
Infection is commonly associated with 
kidney disease, including urinary tract 
infection, glomerulonephritis, transplant 
rejection, and vasculitis. Recent studies 
examined the role of TLRs in the context 
of organ transplantation2 and a variety 
of kidney diseases.3 For instance, TLR7, 
which recognizes single-stranded RNA as 
a ligand, mediates viral infection-induced 
immune-complex glomerulonephritis.5 
TLR11, which fails to respond to known 
TLR ligands, responds specifically to 
uropathogenic bacteria. Mice lacking 
TLR11 are highly susceptible to infection 
of the kidneys by uropathogenic bacteria; 
this indicates a potentially important role 
for TLR11 in preventing infection of the 
urogenital system.6
Observation suggests that TLRs poten-
tially serve a proinflammatory role in 
ischemic/reperfusion injury. For unknown 
reasons, tubular-cell expression of TLR2 is 
enhanced aft er renal ischemic/reperfusion 
injury. Recently, renal-associated TLR2 
was identifi ed as an important initiator 
of infl ammatory responses that lead to 
renal injury and dysfunction in ischemic/
reperfusion injury.7 It is currently not clear 
which endogenous TLR ligands activate 
the innate immune system, leading to the 
development of infl ammation and further 
tissue damage. In addition to necrotic cells, 
it is possible that other, as-yet unknown 
TLR ligands may be responsible for the 
induction of infl ammatory pathways.8 A 
recent study showed that Tamm-Horsfall 
glycoprotein modulates innate immune 
response through activation of TLR4.9 
Future studies need to identify specifi c 
TLR ligands that directly aff ect intrinsic 
renal cells in various kidney diseases.
A recent report suggested that activation 
of innate immunity through TLR4 in the 
donor kidney contributed to the develop-
ment of acute rejection aft er renal trans-
plantation. In this study, the incidence of 
acute allograft  rejection was signifi cantly 
reduced in patients receiving donor graft s 
carrying functional TLR4-Asp299Gly 
and TLR4-Tyr399IIe variants (these 
patients have reduced immune responses 
to lipopolysaccharide), as compared with 
the wild type (22% versus 0%, respectively, 
P = 0.02).10 Th e proposed mechanism is 
that nonspecifi c innate responses can trig-
ger adaptive responses that lead to cellular 
graft  rejection.
An interesting area of future research 
would be to study the role of the innate 
immune response expressed on nonim-
mune cells such as TECs. TECs are known 
to express chemokines, and chemokine 
production is further increased by nonspe-
cifi c stress and injury. Th e molecules that 
trigger, and the mechanisms that regulate, 
TEC cytokine/chemokine secretion are 
poorly characterized and require further 
investigation.
Future studies need to determine the dif-
ferential TLR expression of cells along the 
nephron, identify potential TLR ligands, 
and test strategies to prevent TLR-medi-
ated local infl ammation within the kidney. 
A better understanding of the molecular 
Figure 1 | ‘Danger signals’ caused by ischemic/reperfusion (I/R) injury, alloimmune response, or 
therapeutic interventions to influence gene expression have the potential to serve or release 
ligands, which activate Toll-like receptors (TLRs) expressed along the nephron. This leads to 
upregulation of kidney-derived proinflammatory chemokines and cytokines, attracting effector 
cells and causing renal dysfunction. TIRAP, Toll–interleukin-1 receptor domain-containing adaptor 
protein; TRIF, Toll–interleukin-1 receptor domain-containing adaptor inducing interferon-β.
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processes involved in infectious and non-
infectious TLR signaling in the kidney will 
provide the basis for future strategies to 
interfere with early tubular-cell dysfunc-
tion in kidney disease.
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Homocysteine targeting of plasma 
proteins in hemodialysis patients
DW Jacobsen1,2
Hyperhomocysteinemia, an independent, modifiable risk factor for 
cardiovascular disease, is found in most patients with end-stage renal 
disease. In this issue, Perna et al. examine the extent of protein-S-
linked and protein-N-linked homocysteinylation in uremic patients 
on hemodialysis and the effect of folate treatment on protein 
homocysteinylation. Their findings show that protein-N-linked 
homocysteinylation, but not S-linked homocysteinylation, can be 
normalized by folate therapy.
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There is little doubt that hyperhomo-
cysteinemia is an independent, modifi -
able risk factor for cardiovascular disease. 
However, there is considerable contro-
versy regarding the issues of causality 
and mechanism. Is homocysteine a stealth 
mediator of atherogenesis and disease 
progression, or is it merely an innocent 
marker of the disease process? Patients 
with end-stage renal disease (ESRD) 
generally have mild (>12 to 30 µmol/l 
plasma total homocysteine (tHcy)) to 
intermediate hyperhomocysteinemia (>30 
to 100 µmol/l tHcy), although a presenta-
tion with severe hyperhomocysteinemia 
(>100 µmol/l tHcy) is not uncommon. 
Th e hyperhomocysteinemic state signals 
a breakdown in the homeostatic proc-
esses that regulate homocysteine pro-
duction and consumption. In addition to 
the pathways that consume intracellular 
homocysteine, cells and tissues also export 
this cytotoxic amino acid to circulation to 
maintain a low intracellular steady-state 
concentration. Th e export route serves 
as an escape valve when the consumptive 
metabolic pathways suff er genetic and/or 
acquired insults.
This laboratory has studied the bio-
chemical fate of homocysteine in circula-
tion by in vitro modeling.1,2 Th e original 
intent of these studies was to mechanisti-
cally account for the formation of the enti-
ties that constitute plasma tHcy. Because 
of its highly reactive nature, there is very 
little free reduced homocysteine in cir-
culation, and disulfi de forms account for 
more than 95% of tHcy. We have pro-
posed a model, based on in vitro and in 
vivo studies, to account for the formation 
of these disulfi de forms.2 Small amounts 
(<5% of tHcy) of protein-N-linked homo-
cysteine are found in circulation in addi-
tion to the predominant disulfi de forms of 
homocysteine. Protein-N-linked homo-
cysteine is formed when homocysteine 
thiolactone enters circulation and reacts 
via its activated carbonyl group with an 
ε-amino group of lysine to form a stable 
amide bond.3 Post-translational cova-
lent modification of protein by homo-
cysteine, whether it be N-linked (Figure 
1a) or S-linked (Figure 1b shows only one 
of several reactions leading to S-linked 
homocysteine as we have described1,2), 
has important mechanistic implications, 
as discussed below.
In this issue of Kidney International, 
Perna et al. examine plasma protein 
homocysteinylation in patients with 
ESRD, before and aft er treatment with N-
5-methyltetrahydrofolate.4 As expected, 
mean tHcy was elevated in hemodialysis 
patients compared with controls (57.8 
± 9.9 versus 11.4 ± 1.0 µmol/l). (Assays 
for tHcy measure protein-S-linked 
homocysteine and other disulfi de forms 
but do not measure protein-N-linked 
homocysteine. Therefore, currently 
available clinical diagnostic assays for 
plasma tHcy underestimate actual ‘total’ 
plasma homocysteine by 2%–5%.) Perna 
et al. then determined protein-N-linked 
and protein-S-linked homocysteine in 
controls and patients. Protein-S-linked 
homocysteine was 5.5-fold higher in 
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